Dr Strauss speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about a phase 1 study looking at the safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.

He goes on to discuss that the data from the trial of M7824 suggests a manageable safety profile and an overall response rate of 37.5% in patients with HPV associated cancers including a confirmed overall response rate of 45.5% in patients with known HPV+ disease.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php

свернуть